[go: up one dir, main page]

DE69911441D1 - Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel - Google Patents

Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel

Info

Publication number
DE69911441D1
DE69911441D1 DE69911441T DE69911441T DE69911441D1 DE 69911441 D1 DE69911441 D1 DE 69911441D1 DE 69911441 T DE69911441 T DE 69911441T DE 69911441 T DE69911441 T DE 69911441T DE 69911441 D1 DE69911441 D1 DE 69911441D1
Authority
DE
Germany
Prior art keywords
carnitines
resveratrol
aging
preventing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69911441T
Other languages
English (en)
Other versions
DE69911441T2 (de
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Application granted granted Critical
Publication of DE69911441D1 publication Critical patent/DE69911441D1/de
Publication of DE69911441T2 publication Critical patent/DE69911441T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69911441T 1998-10-09 1999-10-06 Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel Expired - Lifetime DE69911441T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM980636 1998-10-09
IT1998RM000636A IT1302365B1 (it) 1998-10-09 1998-10-09 Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
PCT/IT1999/000311 WO2000021526A1 (en) 1998-10-09 1999-10-06 Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders

Publications (2)

Publication Number Publication Date
DE69911441D1 true DE69911441D1 (de) 2003-10-23
DE69911441T2 DE69911441T2 (de) 2004-07-01

Family

ID=11406160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69911441T Expired - Lifetime DE69911441T2 (de) 1998-10-09 1999-10-06 Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel

Country Status (27)

Country Link
US (1) US6515020B1 (de)
EP (1) EP1117394B1 (de)
JP (1) JP4166951B2 (de)
KR (1) KR20010079981A (de)
CN (1) CN1323205A (de)
AR (1) AR020762A1 (de)
AT (1) ATE249823T1 (de)
AU (1) AU767492B2 (de)
BR (1) BR9915918A (de)
CA (1) CA2344893C (de)
CZ (1) CZ2001920A3 (de)
DE (1) DE69911441T2 (de)
DK (1) DK1117394T3 (de)
EE (1) EE200100205A (de)
ES (1) ES2207287T3 (de)
HK (1) HK1040935A1 (de)
HU (1) HU229364B1 (de)
IL (1) IL142046A0 (de)
IS (1) IS5896A (de)
IT (1) IT1302365B1 (de)
NO (1) NO20011693D0 (de)
PL (1) PL197342B1 (de)
PT (1) PT1117394E (de)
SK (1) SK3782001A3 (de)
TN (1) TNSN99186A1 (de)
TR (1) TR200100947T2 (de)
WO (1) WO2000021526A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047193A (ja) * 2000-07-31 2002-02-12 Sunstar Inc アレルギー性皮膚炎予防または治療用組成物
WO2002038142A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
BRPI0106382B1 (pt) * 2001-03-13 2017-07-11 Universidade Do Estado Do Rio De Janeiro - Uerj Process for obtaining decocts from vitis labrusca and vitis vinifera casts, process for obtaining the hydro-alcoholic extract, process for obtaining the hydro-alcoholic extract-ethyl acetate and pharmaceutical compositions
DE50111204D1 (de) * 2001-08-18 2006-11-23 Cognis Ip Man Gmbh Wirkstoffmischungen
US20070218151A1 (en) * 2002-03-12 2007-09-20 Universidade Do Estado Do Rio De Janeiro Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
KR100574392B1 (ko) * 2003-02-07 2006-05-02 재단법인서울대학교산학협력재단 신경보호활성을 갖는 신규 페닐환 유도체 및 이를함유하는 약학 조성물
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
KR100543056B1 (ko) * 2003-11-07 2006-01-20 (주)네추럴에프앤피 신경세포 보호 활성이 있는 포도씨 추출물을 포함하는뇌질환 예방 및 치료용 조성물
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
ES2245609B1 (es) * 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060121137A1 (en) * 2004-12-07 2006-06-08 Hartle Diane K Muscadine grape pomace in the treatment of intestinal inflammation
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP2322158B1 (de) * 2005-10-26 2020-06-10 Kao Corporation Resveratrol und/oder traubenblattextrakt zur aktivierung des energiemetabolismus
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
US20120016037A1 (en) * 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
WO2008091710A2 (en) * 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
AT506014A1 (de) * 2007-10-24 2009-05-15 Karl Mag Dr Zehethofer Functional drink
US20130203848A1 (en) * 2010-06-16 2013-08-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds useful for increasing neurogenesis in neural tissue
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102919943A (zh) * 2012-10-26 2013-02-13 郑全辉 保健饮品-葡藤素
CN103877170B (zh) * 2012-12-19 2015-11-04 中国医学科学院药用植物研究所 一种虎杖的乙酸乙酯提取物及其制备方法和应用
CN119424497B (zh) * 2025-01-08 2025-06-24 万邦德制药集团有限公司 一种用于防治阿尔茨海默病、皮肤光老化的组合物、制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
CH692837A5 (it) * 1997-07-02 2002-11-29 Lisapharma Spa Composizione farmaceutica per uso alimentare, dietetico o medicinale adatta a migliorare l'assorbimento orale dei polifenoli e particolarmente del resveratrolo presenti nell'uva e nei suoi p
US5904924A (en) 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase

Also Published As

Publication number Publication date
DE69911441T2 (de) 2004-07-01
AU6121399A (en) 2000-05-01
HU229364B1 (en) 2013-11-28
HK1040935A1 (zh) 2002-06-28
ATE249823T1 (de) 2003-10-15
NO20011693L (no) 2001-04-04
PL347209A1 (en) 2002-03-25
BR9915918A (pt) 2001-08-21
EP1117394B1 (de) 2003-09-17
IT1302365B1 (it) 2000-09-05
EP1117394A1 (de) 2001-07-25
DK1117394T3 (da) 2004-01-26
WO2000021526A1 (en) 2000-04-20
SK3782001A3 (en) 2001-10-08
AR020762A1 (es) 2002-05-29
HUP0104021A3 (en) 2003-12-29
EE200100205A (et) 2002-06-17
US6515020B1 (en) 2003-02-04
CZ2001920A3 (cs) 2001-08-15
CA2344893C (en) 2008-07-29
PT1117394E (pt) 2004-02-27
TNSN99186A1 (fr) 2005-11-10
ES2207287T3 (es) 2004-05-16
ITRM980636A1 (it) 2000-04-10
CN1323205A (zh) 2001-11-21
NO20011693D0 (no) 2001-04-04
JP2002527389A (ja) 2002-08-27
AU767492B2 (en) 2003-11-13
PL197342B1 (pl) 2008-03-31
KR20010079981A (ko) 2001-08-22
CA2344893A1 (en) 2000-04-20
JP4166951B2 (ja) 2008-10-15
IS5896A (is) 2001-03-16
IL142046A0 (en) 2002-03-10
TR200100947T2 (tr) 2001-07-23
HUP0104021A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
DE69911441D1 (de) Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
DE69822919D1 (de) Spezifische Antikörper zur Verwendung in der Herstellung pharmazeutischer Zusammensetzungen nützlich für die Vorbeugung oder Behandlung von Gastritis, Magen- und Zwölffingerdarmgeschwüren
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69913975D1 (de) Verfahren und vorrichtung für die herstellung von deodorant oder schweisshemmender zusammensetzung
DE69910863D1 (de) Verfahren zur Herstellung von Calciumfluorid und Calciumfluorid für Fotolithographie
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
BR9507010A (pt) Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
ATE389409T1 (de) Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69716251D1 (de) Verwendung von oktoxyglyzerin in einer kosmetische und/oder dermatologische zusammensetzung zur behandlung von seborrhea und akne
DE59500879D1 (de) Mittel zur Wasserbehandlung mit Polyasparaginsäure oder einem Derivat davon und Phosphonsäure
ATE229502T1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
EP1005345A4 (de) Methode und zusammensetzungen zur behandlung von allergischem asthma und anderen beschwerden mittels descarboethoxyloratadin
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE278400T1 (de) Zusammensetzungen für die verwendung bei der behandlung und prävention von hyperurikämie
DE69512288D1 (de) Verfahren zur Herstellung von Hexafluorpropan und Perfluorpropan
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
DE59504187D1 (de) Verfahren zur Herstellung von ultrareinem Bisphenol-A und dessen Verwendung
DE59500700D1 (de) Verfahren und Mittel zur Herstellung von purpurfarbenen Dekoren
DE60100930D1 (de) Resistzusammensetzung und Verfahren zur Herstellung von Halbleiterbauelementen
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE59705697D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition